08642961 Search Results


v v baby rabbit complement mp biomedicals  (Valiant Co Ltd)
94
Valiant Co Ltd v v baby rabbit complement mp biomedicals
(a) ADCC and (b) CDC activity of chAb735 variants (blue bars) and wt chAb735 (red bars) against SW2 tumor cells. For ADCC assays, effector PBMCs to target SW2 cell ratios of 20:1 were used. For CDC assays, baby rabbit <t>complement</t> was used at a final concentration of 10% (v/v). Cytotoxicity was assayed over a range of IgG concentrations in the presence (+) or absence (-) of PBMCs or complement, with representative results depicted for 0.1 ng/mL and 1 μg/mL in bar graphs at left. Isotype chAb in the presence of PBMCs/complement or chAb735 and chAb735 D158G/A230G in the absence of PBMCs/complement served as negative controls (gray bars). Data are average of biological replicates ( n = 3) ± SD. Statistical significance was determined by unpaired two-tailed Student’s t- test. Calculated p values are represented as follows: *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; ns, not significant.
V V Baby Rabbit Complement Mp Biomedicals, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/v v baby rabbit complement mp biomedicals/product/Valiant Co Ltd
Average 94 stars, based on 1 article reviews
v v baby rabbit complement mp biomedicals - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

Image Search Results


(a) ADCC and (b) CDC activity of chAb735 variants (blue bars) and wt chAb735 (red bars) against SW2 tumor cells. For ADCC assays, effector PBMCs to target SW2 cell ratios of 20:1 were used. For CDC assays, baby rabbit complement was used at a final concentration of 10% (v/v). Cytotoxicity was assayed over a range of IgG concentrations in the presence (+) or absence (-) of PBMCs or complement, with representative results depicted for 0.1 ng/mL and 1 μg/mL in bar graphs at left. Isotype chAb in the presence of PBMCs/complement or chAb735 and chAb735 D158G/A230G in the absence of PBMCs/complement served as negative controls (gray bars). Data are average of biological replicates ( n = 3) ± SD. Statistical significance was determined by unpaired two-tailed Student’s t- test. Calculated p values are represented as follows: *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; ns, not significant.

Journal: bioRxiv

Article Title: Engineering affinity-matured variants of an anti-polysialic acid monoclonal antibody with superior cytotoxicity-mediating potency

doi: 10.1101/2025.02.12.637914

Figure Lengend Snippet: (a) ADCC and (b) CDC activity of chAb735 variants (blue bars) and wt chAb735 (red bars) against SW2 tumor cells. For ADCC assays, effector PBMCs to target SW2 cell ratios of 20:1 were used. For CDC assays, baby rabbit complement was used at a final concentration of 10% (v/v). Cytotoxicity was assayed over a range of IgG concentrations in the presence (+) or absence (-) of PBMCs or complement, with representative results depicted for 0.1 ng/mL and 1 μg/mL in bar graphs at left. Isotype chAb in the presence of PBMCs/complement or chAb735 and chAb735 D158G/A230G in the absence of PBMCs/complement served as negative controls (gray bars). Data are average of biological replicates ( n = 3) ± SD. Statistical significance was determined by unpaired two-tailed Student’s t- test. Calculated p values are represented as follows: *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; ns, not significant.

Article Snippet: Ten-fold serial dilutions of IgGs starting at 10 μg/ml were added in the presence of 10% (v/v) baby rabbit complement (MP Biomedicals) and incubated for 3 h. Cells treated with wt chAb735 and chAb735 D158G/A230G in the absence of complement or with an isotype chAb in the presence of complement served as negative controls.

Techniques: Activity Assay, Concentration Assay, Two Tailed Test